MRK Stock Overview
Operates as a healthcare company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Merck & Co., Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$99.86 |
| 52 Week High | US$134.63 |
| 52 Week Low | US$94.48 |
| Beta | 0.41 |
| 11 Month Change | -6.36% |
| 3 Month Change | -14.36% |
| 1 Year Change | -1.79% |
| 33 Year Change | 21.37% |
| 5 Year Change | 13.98% |
| Change since IPO | 8,776.44% |
Recent News & Updates
The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business
Nov 15
Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
Nov 14Recent updates
The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business
Nov 15Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
Nov 14Merck: An Undervalued Dividend Machine
Nov 07Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat
Oct 25Market Still Lacking Some Conviction On Merck & Co., Inc. (NYSE:MRK)
Oct 15Merck Is At Support And Should Go Higher (Technical Analysis)
Oct 07Merck Appears Ready To Return To June Highs (Technical Analysis)
Sep 14Merck's Change To Profit Guidance Provides An Opportunity
Sep 01Merck: Buy This Bargain Before It's Gone
Aug 12Shareholder Returns
| MRK | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.5% | -1.4% | 0.3% |
| 1Y | -1.8% | 10.8% | 31.1% |
Return vs Industry: MRK underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: MRK underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| MRK volatility | |
|---|---|
| MRK Average Weekly Movement | 2.5% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MRK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MRK's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1891 | 71,000 | Rob Davis | www.merck.com |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Merck & Co., Inc. Fundamentals Summary
| MRK fundamental statistics | |
|---|---|
| Market cap | US$246.49b |
| Earnings (TTM) | US$12.15b |
| Revenue (TTM) | US$63.17b |
20.8x
P/E Ratio4.0x
P/S RatioIs MRK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRK income statement (TTM) | |
|---|---|
| Revenue | US$63.17b |
| Cost of Revenue | US$14.79b |
| Gross Profit | US$48.39b |
| Other Expenses | US$36.24b |
| Earnings | US$12.15b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 04, 2025
| Earnings per share (EPS) | 4.80 |
| Gross Margin | 76.59% |
| Net Profit Margin | 19.23% |
| Debt/Equity Ratio | 85.6% |
How did MRK perform over the long term?
See historical performance and comparison